# Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

> **NCT03488225** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia in Remission
- B Acute Lymphoblastic Leukemia
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin Hydrochloride
- **BIOLOGICAL:** Inotuzumab Ozogamicin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Leucovorin Calcium
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **BIOLOGICAL:** Ofatumumab
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT03488225
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-28
- **Primary completion:** 2020-04-02
- **Final completion:** 2020-04-02
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** the study was closed early due to competing trials
- **Last updated:** 2024-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03488225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03488225, "Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03488225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*